# Supplements, Placebo, or Rosuvastatin Study

Study · id `cardio:ct-nct04846231` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04846231](<https://clinicaltrials.gov/study/NCT04846231>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04846231

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

## Technical summary

Registry record NCT04846231. Randomized; triple masking; primary purpose treatment. Start 2021-04-23 (actual); primary completion 2022-07-19 (actual). Results posted on 2023-05-25.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 203 participants (enrolled count; ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Started: 2021-04-23 (actual) (ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Primary completion: 2022-07-19 (actual) (ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Completion: 2022-07-19 (actual) (ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Results first posted: 2023-05-25 (ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04846231, source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04846231-2023-05-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Supplements, Placebo, or Rosuvastatin Study
- Acronym: SPORT
- Condition: Hypercholesterolemia
- Intervention (Dietary supplement): Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice
- Intervention (Drug): Rosuvastatin
- Intervention (Other): Placebo
- Lead sponsor: The Cleveland Clinic
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: The Cleveland Clinic (`cardio:org-the-cleveland-clinic`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers (`cardio:pubmed-36351465`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d05244a7b341d1d4ba6a8c8249b6d22113c204ec47ac62850c2f361b40397f42
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
